losartan has been researched along with verapamil in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (25.00) | 18.2507 |
| 2000's | 10 (35.71) | 29.6817 |
| 2010's | 10 (35.71) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Assaraf, YG; Borgnia, MJ; Eytan, GD | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Avdeef, A; Tam, KY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baker, KM; Dostal, DE; Du, J; Motel, TJ; Thekkumkara, TJ; Thomas, WG | 1 |
| Heidland, A; Ling, H; Schaefer, L; Schaefer, RM; Schnittler, HJ; Vamvakas, S | 1 |
| Cohen, A; Erlich, Y; Rosenmann, E; Rosenthal, T | 1 |
| Barton, M; d'Uscio, LV; Lüscher, TF; Shaw, S | 1 |
| Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H | 1 |
| Borges, AC; Paiva, TB; Prioste, RN; Shimuta, SI | 1 |
| Lazareth, I | 1 |
| Anders, RJ; Bakris, G; Fagan, T; Ram, V; Sica, D; Vaitkus, PT | 1 |
| Armenteros, S; Fernández González, R; Garrido, J; Goicolea, I; Martínez, JM; Moreno Carretero, E; Piniés, J | 1 |
| Anders, RJ; Calhoun, D; Mansoor, GA; Sica, DA; White, WB | 1 |
| Bacher, P; Bakris, G; Champion, A; Molitch, M; Sarafidis, P; Sowers, JR; Zhou, Q | 1 |
| Baskurt, M; Kaya, A; Kucukoglu, S; Okcun, B; Ortak, K; Yigit, Z; Yildiz, A | 1 |
| Kamiyama, E; Mikkaichi, T; Nakai, D; Okazaki, O; Okudaira, N | 1 |
| Buck, A; Calcinaghi, N; Fritschy, JM; Jolivet, R; Keller, AL; Matter, CM; Singh, A; Weber, B; Winnik, S; Wyss, MT | 1 |
| Böhmer, FD; Kirches, E; Mawrin, C; Pachow, D; Petermann, A; Wallesch, M; Wilisch-Neumann, A | 1 |
| Bozic, M; Fernandez, E; Freixenet, M; Lopez, I; Panizo, S; Pascual, J; Riera, M; Sevilla, MA; Soler, MJ; Valdivielso, JM | 1 |
| Awadalla, A; Barakat, TS; El-Ghar, MA; El-Nahas, AR; Elsaadany, MM; Elsawy, EA; Elshal, AM; Ismail, AM; Saleh, HH; Sheir, KZ; Taha, DE; Wafa, EW | 1 |
| Chen, WB; Chen, YS; Liu, YQ; Qin, ZC; Sun, YY; Zhang, SY | 1 |
2 review(s) available for losartan and verapamil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Management of Raynaud's phenomenon].
Topics: Adult; Age Distribution; Calcium Channel Blockers; Female; Humans; Iloprost; Losartan; Male; Middle Aged; Necrosis; Prognosis; Raynaud Disease; Risk Factors; Sex Distribution; Smoking; Vasodilator Agents; Verapamil | 2001 |
6 trial(s) available for losartan and verapamil
| Article | Year |
|---|---|
A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Delayed-Action Preparations; Double-Blind Method; Enalapril; Female; Heart Rate; Humans; Hypertension; Losartan; Male; Middle Aged; Vasodilator Agents; Verapamil | 2002 |
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood Pressure; Carbohydrate Metabolism; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydrochlorothiazide; Hypertension; Indoles; Lipids; Losartan; Male; Middle Aged; Prospective Studies; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Sodium Chloride Symporter Inhibitors; Treatment Outcome; Vasodilator Agents; Verapamil | 2002 |
Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising.
Topics: Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Delayed-Action Preparations; Double-Blind Method; Electrocardiography, Ambulatory; Enalapril; Female; Heart Rate; Humans; Hypertension; Losartan; Male; Statistics, Nonparametric; Systole; Verapamil | 2002 |
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.
Topics: Analysis of Variance; Chi-Square Distribution; Diabetes Mellitus; Diuretics; Female; Glucose Tolerance Test; Humans; Hydrochlorothiazide; Hypertension; Indoles; Insulin Resistance; Losartan; Male; Metabolic Syndrome; Middle Aged; Renin-Angiotensin System; Verapamil | 2008 |
Comparison of rate and rhythm control in hypertension patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Calcium Channel Blockers; Cardiotonic Agents; Digoxin; Electric Countershock; Female; Follow-Up Studies; Humans; Hypertension; Losartan; Male; Metoprolol; Middle Aged; Survival Analysis; Treatment Outcome; Verapamil | 2008 |
A randomised controlled trial evaluating renal protective effects of selenium with vitamins A, C, E, verapamil, and losartan against extracorporeal shockwave lithotripsy-induced renal injury.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antioxidants; Ascorbic Acid; Calcium Channel Blockers; Drug Therapy, Combination; Female; Humans; Kidney; Lithotripsy; Losartan; Male; Selenium; Verapamil; Vitamin A; Vitamin E; Vitamins; Wounds and Injuries | 2017 |
20 other study(ies) available for losartan and verapamil
| Article | Year |
|---|---|
Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; CHO Cells; Clone Cells; Computer Simulation; Cricetinae; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Emetine; Gramicidin; Ionophores; Kinetics; Mathematics; Models, Theoretical; N-Formylmethionine Leucyl-Phenylalanine; Oligopeptides; Valinomycin | 1996 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Stable expression of a functional rat angiotensin II (AT1A) receptor in CHO-K1 cells: rapid desensitization by angiotensin II.
Topics: Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Base Sequence; Calcium; Cell Membrane; CHO Cells; Concanavalin A; Cricetinae; Gene Expression; Guanosine Triphosphate; Imidazoles; Losartan; Membrane Potentials; Molecular Sequence Data; Pyridines; Rats; Receptors, Angiotensin; Tetradecanoylphorbol Acetate; Tetrazoles; Transfection; Verapamil | 1995 |
Angiotensin-II-induced cell hypertrophy: potential role of impaired proteolytic activity in cultured LLC-PK1 cells.
Topics: Analysis of Variance; Angiotensin II; Animals; Biphenyl Compounds; Calcium; Calcium Channel Blockers; Cell Count; Cells, Cultured; Cycloheximide; DNA; Hypertrophy; Imidazoles; Kidney; LLC-PK1 Cells; Losartan; Oligopeptides; Protein Synthesis Inhibitors; Proteins; Swine; Tetrazoles; Verapamil | 1995 |
Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Disease Models, Animal; Enalapril; Glucose; Hypertension; Imidazoles; Losartan; Male; Rats; Rats, Inbred Strains; Tetrazoles; Verapamil | 1997 |
Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Calcium Channel Blockers; Data Interpretation, Statistical; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Hypertension; In Vitro Techniques; Losartan; Male; Muscle, Smooth, Vascular; Nitroprusside; Rats; Rats, Inbred WKY; Receptors, Endothelin; Time Factors; Vasoconstriction; Vasodilation; Vasodilator Agents; Verapamil | 1998 |
Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats.
Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Body Weight; Calcium Channel Blockers; Cholesterol; Glucocorticoids; Hypertension; Imidazoles; Imidazolidines; Losartan; Male; Methylprednisolone; Nephrosis; Proteinuria; Rats; Rats, Inbred Dahl; Sodium Chloride, Dietary; Verapamil | 1998 |
Different pathways for Ca2+ mobilization by angiotensin II and carbachol in the circular muscle of the guinea-pig ileum.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Calcium; Calcium Channel Blockers; Carbachol; Electric Stimulation; Female; Guinea Pigs; Ileum; Imidazoles; In Vitro Techniques; Isradipine; Losartan; Male; Membrane Potentials; Muscarinic Agonists; Muscle Contraction; Muscle, Smooth; Nickel; Nifedipine; Potassium Chloride; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrodotoxin; Vasoconstrictor Agents; Verapamil | 1999 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Determination; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Complications; Diltiazem; Diuretics; Drug Evaluation; Health Behavior; Humans; Hypertension; Losartan; Obesity; Renal Insufficiency; Sodium; Stroke; Verapamil | 2005 |
Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes.
Topics: Adenosine Triphosphatases; Angiotensin II Type 1 Receptor Blockers; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Benzoates; Biological Transport; Biphenyl Compounds; Caco-2 Cells; Calcium Channel Blockers; Cardiotonic Agents; Cell Membrane; Digoxin; Drug Interactions; Humans; Irbesartan; Losartan; Telmisartan; Tetrazoles; Verapamil | 2010 |
Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular Circulation; Disease Models, Animal; Hypertension; Losartan; Male; Microscopy, Fluorescence, Multiphoton; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Spectrometry, X-Ray Emission; Verapamil | 2013 |
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hydroxyurea; Losartan; Meningeal Neoplasms; Meningioma; Metformin; Mifepristone; Neurofibromin 2; Promoter Regions, Genetic; Quinazolines; Radiation Tolerance; Tamoxifen; Temozolomide; Tumor Suppressor Proteins; Verapamil | 2014 |
High phosphate diet increases arterial blood pressure via a parathyroid hormone mediated increase of renin.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Diet; Kidney; Losartan; Male; Parathyroid Hormone; Parathyroidectomy; Phosphates; Rats; Rats, Sprague-Dawley; Renin; Renin-Angiotensin System; Verapamil | 2014 |
Losartan Potassium and Verapamil Hydrochloride Compound Transdermal Drug Delivery System: Formulation and Characterization.
Topics: Administration, Cutaneous; Delayed-Action Preparations; Drug Delivery Systems; Losartan; Skin Absorption; Verapamil | 2022 |